Mazo, G., and A. Kibitov. “Genetic Markers of Metabolic Side-Effects Risks in Second-Generation Antipsychotic Therapy”. Current Therapy of Mental Disorders, no. 4, Dec. 2017, pp. 2-10, doi:10.21265/PSYPH.2017.43.8415.